Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Gastroenterology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT05665608

Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation

Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT05665608.

📅 01 Apr 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT05665608
Sponsor
Charite University, Berlin, Germany
Start
2023-11-16
ClinicaliQ Trial Snapshot
  • Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT05665608.
  • Patients who have survived a myocardial infarction (MI) are at increased risk for sudden cardiac death (SCD) caused by ventricular tachycardia and ventricular fibrillation. A severely reduced left ventricular ejection fraction (LVEF) as a rough overall measure of impaired heart function after….
  • Sponsor: Charite University, Berlin, Germany.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Patients who have survived a myocardial infarction (MI) are at increased risk for sudden cardiac death (SCD) caused by ventricular tachycardia and ventricular fibrillation. A severely reduced left ventricular ejection fraction (LVEF) as a rough overall measure of impaired heart function after MI was shown to indicate a higher risk for SCD. Based on this observation, two landmark randomised trials, MADIT II and SCD-HeFT, were conducted between end of the 1990s and early 2000s. These trials compared the survival of patients with severely reduced LVEF who received an implantable cardioverter-defibrillator…

Eligibility Snapshot
  • : 1. Age ≥18 years. 2. Naïve to implantation of any pacemaker or defibrillator 3. Documented history of MI either as ST segment elevation myocardial infarction (STEMI) or as non-ST segment elevation myocardial infarction (NSTEMI) at least 3 months prior to enrolment. 4. Symptomatic heart failure with New York Heart Association (NYHA) class II or III. 5. On OMT for at least 3 months prior to enrolment. 6. LVEF ≤ 35% (at transthoracic echocardiography or cardiac magnetic resonance imaging [MRI] at least 3 months after MI). 7. Signed informed consent. Inclusion criterion I3 defines myocardial infarction according to the 2018 ESC/ACC/AHA/WHF Fourth Universal Definition of myocardial infarction

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Percutaneous insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock
Cardiology / Cardiovascular · 25 Mar 2026
Percutaneous insertion of catheter-based left ventricular microaxial flow pumps may be considered for patients with acute cardiogenic shock refractory to medical therapy…
View guideline →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Guideline
Empagliflozin for Treating Chronic Heart Failure with Reduced Ejection Fraction (NICE TA773)
Cardiology / Cardiovascular · 27 Mar 2026
Initiate empagliflozin 10 mg once daily as add-on therapy to standard HFrEF treatment (ACE inhibitors, beta-blockers, and aldosterone antagonists) in adults with…
View guideline →
Guideline
Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock
Cardiology / Cardiovascular · 25 Mar 2026
Insert a catheter-based left ventricular microaxial flow pump in patients with acute cardiogenic shock refractory to medical therapy and inotropic support, as…
View guideline →
Guideline
Heart Failure: Diagnosis and Management (NICE NG106)
Cardiology / Cardiovascular · 27 Mar 2026
Use NT-BNP or BNP testing in primary care to rule out heart failure; refer urgently to secondary care if elevated with compatible…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →